南财智讯11月26日电，奥锐特公告，公司高管赵珍平先生因个人资金需求，通过集中竞价方式减持公司 股票62,500股，占公司总股本的0.02%，本次减持计划已实施完毕。减持期间为2025年11月4日至2025年 11月25日，减持价格区间为22.00～23.50元/股，减持总金额为141.63万元。本次实际减持情况与此前披 露的减持计划一致，减持计划已完成。 ...

Core Viewpoint - Aorite Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of a combined packaging of estradiol tablets and estradiol/dydrogesterone tablets, which is expected to enhance the company's market competitiveness and positively impact its operating performance [1][5][6]. Group 1: Drug Registration Information - The drug is named estradiol tablets/estradiol/dydrogesterone tablets combined packaging, with a registration number of 2025S03486 [1]. - The formulation includes estradiol 2mg and dydrogesterone 10mg [1]. - The drug is classified as a Class 4 chemical drug and is produced by Aorite's subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd. [1][2]. Group 2: Market Situation - The drug is indicated for the treatment of menopausal syndrome caused by natural or surgical menopause [2]. - The drug was originally developed by Abbott B.V. and was approved for domestic sale in 2015 under the brand name "Fentam." [3]. - As of now, there are two companies, Abbott and Yangzhou Aorite, that have passed the consistency evaluation for this drug in China [3]. Group 3: Financial Investment - As of October 31, 2025, the company has invested approximately 12.64 million RMB in the research and development of this drug [4]. - The hospital sales revenue for "Fentam" is projected to be 564 million RMB in 2024 [4]. Group 4: Impact on Company - The approval of the drug registration is expected to enhance the company's competitiveness in the pharmaceutical market [5]. - The new product's market entry is anticipated to have a positive effect on the company's financial performance [5].

证券日报网讯 11月25日晚间，奥锐特发布公告称，近日，公司全资子公司扬州奥锐特药业有限公司收 到国家药品监督管理局核准签发的一份雌二醇片/雌二醇地屈孕酮片复合包装《药品注册证书》。 （文章来源：证券日报） ...

该药品是由Abbott B.V.公司研发的一款地屈孕酮复合制剂，用于治疗自然或术后绝经所致的围绝经期综 合征等。2015年由雅培申请的雌二醇片/雌二醇地屈孕酮片复合包装，作为进口药品获得批准在国内上 市，其商品名为"芬吗通®"。 格隆汇11月25日丨奥锐特(605116.SH)公布，近日，公司全资子公司扬州奥锐特收到国家药监局核准签 发的一份雌二醇片/雌二醇地屈孕酮片复合包装《药品注册证书》，药品名称：雌二醇片/雌二醇地屈孕 酮片复合包装，药品批准文号：国药准字H20256016。 本次扬州奥锐特的雌二醇片/雌二醇地屈孕酮片复合包装按照化学药品新注册分类方法获得药品注册批 件，有利于提升公司在该药品领域的市场竞争力，同时新批准产品在国内上市销售，有望对公司经营业 绩产生积极影响。 ...

Core Viewpoint - The company, Aorite (605116.SH), has received approval from the National Medical Products Administration for a combined packaging of estradiol tablets and estradiol-dydrogesterone tablets, which is expected to enhance its market competitiveness and positively impact its financial performance [1]. Group 1 - Aorite's wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., has obtained a drug registration certificate for the combined packaging of estradiol tablets and estradiol-dydrogesterone tablets [1]. - The approved product is intended for the treatment of perimenopausal syndrome caused by natural or surgical menopause [1]. - The registration of the product under the new classification method for chemical drugs is expected to improve the company's market position in this therapeutic area [1].

每经AI快讯，奥锐特（SH 605116，收盘价：22元）11月25日晚间发布公告称，近日，奥锐特药业股份 有限公司全资子公司扬州奥锐特药业有限公司收到国家药品监督管理局核准签发的一份雌二醇片/雌二 醇地屈孕酮片复合包装《药品注册证书》。产品名称为"雌二醇片/雌二醇地屈孕酮片复合包装"。 2025年1至6月份，奥锐特的营业收入构成为：自产原料药及中间体占比85.12%，制剂占比11.64%，贸 易占比2.74%，其他业务占比0.5%。 每经头条（nbdtoutiao）——688496，被证监会立案！刚上市业绩就变脸，亏损超1亿元；核心产品受重 创：第一大客户"自产自用"，减少采购 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 截至发稿，奥锐特市值为89亿元。 ...

Core Viewpoint - Aorite (605116.SH) announced that its wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for a combination packaging of estradiol tablets and estradiol/dydrogesterone tablets, which is intended for the treatment of perimenopausal syndrome caused by natural or surgical menopause [1] Group 1 - The newly approved product, branded as "Aoshutong," is classified under the new registration category for chemical drugs, which enhances the company's market competitiveness in this pharmaceutical area [1] - The approval of this product is expected to have a positive impact on the company's operational performance due to its anticipated domestic market launch [1]

证券代码：605116 证券简称：奥锐特 公告编号：2025-084 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 注册分类：化学药品4类 上市许可持有人：扬州奥锐特药业有限公司 关于全资子公司获得药品注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，奥锐特药业股份有限公司（以下简称"奥锐特"或"公司"）全资子 公司扬州奥锐特药业有限公司（以下简称"扬州奥锐特"）收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的一份雌二醇片/雌二醇地屈孕酮片复 合包装（以下简称"该药品"）《药品注册证书》，现将相关情况公告如下： 一、注册证书基本信息 药品名称：雌二醇片/雌二醇地屈孕酮片复合包装 批件号：【2025S03486】 剂型：片剂 规格：雌二醇片含雌二醇2mg；雌二醇地屈孕酮片含雌二醇2mg和地屈孕酮 10mg 申请事项：药品注册（境内生产） 药品生产企业：扬州奥锐特药业有限公司 药品批准文号：国药准字H20256016 审评结论：根据《中华人民共和国药品管理法》及有关规定，经审查 ...

智通财经APP讯，奥锐特(605116.SH)发布公告，近日，公司全资子公司扬州奥锐特药业有限公司(简 称"扬州奥锐特")收到国家药品监督管理局核准签发的一份雌二醇片/雌二醇地屈孕酮片复合包装《药品 注册证书》。该药品用于治疗自然或术后绝经所致的围绝经期综合征。 本次扬州奥锐特的雌二醇片/雌二醇地屈孕酮片复合包装(注册商标"奥舒桐")按照化学药品新注册分类方 法获得药品注册批件，有利于提升公司在该药品领域的市场竞争力，同时新批准产品在国内上市销售， 有望对公司经营业绩产生积极影响。 ...

格隆汇11月21日丨奥锐特(605116.SH)公布，自2025年11月1日至2025年11月21日，公司通过上海证券交 易所交易系统以集中竞价交易方式已累计回购公司股份222.47万股，占公司目前总股本的比例为 0.55%，回购成交的最高价为22.59元/股，最低价为18.83元/股，支付的资金总额为人民币4623.11万元 （不含交易费用）。 ...